MedTrace Logo

Quantification of Immune Cells in Women Using Contraception (CHIC II)

NCT01873170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 326

Last updated 2021-12-27

No results posted yet for this study

Summary

This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV.

Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA), the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women who are not using birth control and who are not at risk of pregnancy for comparison.

Conditions

  • HIV
  • Immune Cells (Mucosal and Systemic)
  • Contraception

Interventions

DRUG

levonorgestrel exposure

DRUG

DMPA exposure

DRUG

etonogestrel exposure

DEVICE

IUD insertion

DEVICE

subdermal contraceptive implant insertion

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Beatrice Chen, MD, MPH · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-02-20
Completion
2020-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01873170 on ClinicalTrials.gov